【摘要】 目的:研究谷胱甘肽硫转移酶(GSTs)基因多态性与环磷酰胺在难治性肾病综合征的不良反应关系。方法:运用等位基因特异性PCR(ASPCR)和PCR-限制性片段长度多态性(PCR-RFLP)的方法分析谷胱甘肽硫转移酶基因型;参照SFDA的不良反应分析标准分析环磷酰胺在难治性肾病综合征的不良反应。结果:骨髓抑制组和胃肠道反应组含有GSTP1(I/V或V/V)的机率高于无骨髓抑制组和无胃肠道反应组,GSTP1(I/V或V/V)组患者发生骨髓抑制和胃肠道反应机率高于GSTP1(I/I)组患者。结论:环磷酰胺治疗前检测GSTs基因多态性有助于避免骨髓抑制和胃肠道反应的发生。更多还原

【Abstract】 OBJECTIVE To study the relation of glutathione S-transferase genotype with the adverse drug reaction of cyclophosphamide in nephritic syndrome patients.METHODS Glutathione S-transferase polymorphisms were analyzed by ASPCR and the PCR-RFLP method,Refractory nephrotic syndrome adverse reactions of cyclophosphamide were analyzed using SFDA ADR criteria.RESULTS The frequency of gastrointestinal reactions containing GSTP1(I/V or V/V)of marrow suppression is higher than those without gastrointestinal tract Reaction Group and without marrow suppression group(I/V or V/V).The frequency of marrow suppression and gastric intestinal reaction of GSTP1(I/V or V/V)group is higher than GSTP1(I/I)group.CONCLUSION Patients with mutation alleles of GSTP1 are likely to have bone marrow suppression and gastrointestinal reactions.To detect the glutathione S-transferase genotype before using cyclophosphamide is significant to improve the therapeutic safety.更多还原